8-K filed November 20, 2024, 6:59 PM ET ticker RXRX CIK 0001601830

M&A confidence high sentiment neutral materiality 0.85

RECURSION PHARMACEUTICALS, INC. (RXRX): M&A transaction — Recursion completes Exscientia acquisition; issues 102M shares, names new CFO

RECURSION PHARMACEUTICALS, INC.

Acquisition of Exscientia effective Nov 20, 2024 via UK scheme; 0.7729 Recursion shares per Exscientia share; 102,138,419 shares issued.
Exscientia ADSs (EXAI) delisted from Nasdaq; equity awards converted to Recursion options/RSUs using Exchange Ratio.
CFO Michael Secora steps down; Ben Taylor (Exscientia's former CFO) appointed CFO of Recursion and President of Recursion UK.
COO Tina Marriott transitions to Executive Advisor; CEO Chris Gibson adds President role; David Hallet named CSO; other exec promotions.
Board expands to 8; Franziska Michor appointed Class II director. 2024 Inducement Equity Plan adopted, reserving 17.5M shares.

item 2.01 item 5.02 item 7.01 item 8.01 item 9.01 item 6.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Michael Secora

Chief Financial Officer

RXRX · RECURSION PHARMACEUTICALS, INC.

Effective: 2024-11-20
Successor: Ben Taylor
Filed: November 20, 2024, 6:59 PM ET

Michael Secora On November 20, 2024, the Company announced that Michael Secora (“Dr. Secora”), Chief Financial Officer of the Company, will be transitioning from his role as Chief Financial Officer, effective as of November 20, 2024.

Appointed

Franziska Michor

Class II Director

RXRX · RECURSION PHARMACEUTICALS, INC.

Effective: 2024-11-20
Filed: November 20, 2024, 6:59 PM ET

the Board increased the number of members of the Board from 7 to 8 and appointed Franziska Michor, Ph.D., (“Dr. Michor”) as a Class II Director of the Board

Appointed

Ben Taylor

Chief Financial Officer of the Company and President of Recursion UK

RXRX · RECURSION PHARMACEUTICALS, INC.

Effective: 2024-11-20
Filed: November 20, 2024, 6:59 PM ET

Ben Taylor On November 20, 2024, the Board appointed Ben Taylor (“Mr. Taylor”), age 47, as Chief Financial Officer of the Company and President of Recursion UK, effective as of November 20, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Secora changed role as Chief Financial Officer at RECURSION PHARMACEUTICALS, INC..

Action: transitioned from
Role: Chief Financial Officer

Exact text from the filing

Michael Secora On November 20, 2024, the Company announced that Michael Secora (“Dr. Secora”), Chief Financial Officer of the Company, will be transitioning from his role as Chief Financial Officer, effective as of November 20, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Franziska Michor was appointed as Class II Director at RECURSION PHARMACEUTICALS, INC..

Action: appointed
Role: Class II Director

Exact text from the filing

the Board increased the number of members of the Board from 7 to 8 and appointed Franziska Michor, Ph.D., (“Dr. Michor”) as a Class II Director of the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ben Taylor was appointed as Chief Financial Officer of the Company and President of Recursion UK at RECURSION PHARMACEUTICALS, INC..

Action: appointed
Role: Chief Financial Officer of the Company and President of Recursion UK

Exact text from the filing

Ben Taylor On November 20, 2024, the Board appointed Ben Taylor (“Mr. Taylor”), age 47, as Chief Financial Officer of the Company and President of Recursion UK, effective as of November 20, 2024.

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

RECURSION PHARMACEUTICALS, INC. completed an acquisition involving Exscientia plc for 0.7729 shares of Class A Common Stock per Exscientia Ordinary Share (closed 2024-11-20).

Action: acquisition
Counterparty: Exscientia plc
Consideration: 0.7729 shares of Class A Common Stock per Exscientia Ordinary Share
Closing: 2024-11-20

Exact text from the filing

(each a “Scheme Share”) was acquired by Recursion (or, at Recursion’s direction, by a nominee) from the holders of the Scheme Shares (each a “Scheme Shareholder”) in exchange for 0.7729 shares of Class A Common Stock (the “Company Class A Common Stock”) of the Company, par value of $0.00001 per share (the “Share Deliverable” and collectively the “Exchange

View on SEC.gov

12 m&a transactions filed in the last 30 days. Browse all m&a transactions →

RECURSION PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001601830-24-000217

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.